Day 2

Gain insight into today’s sessions so you can get the most out of your conference experience.

Valuable insights can be drawn from international examples of navigating market access. Understand different international pricing models, regulatory landscapes, and reimbursement strategies, along with recommendations. Master the success factors to:

• Compare key approaches to market access with a view to identifying best practices applicable to the Canadian landscape.
• Explore international market access pathways and supporting projects.
• Learn how global regulatory trends and policy shifts impact Canadian market access and which proactive strategies can be implemented for long-term success.

Perfect a future-proof approach to market access with insights from beyond Canada’s borders.

Ensuring robust pharmaceutical supply chains is essential for maintaining consistent drug availability and safeguarding public health. Develop key strategies to enhance your supply chain resilience. Source your plan of action by:

• Diversifying manufacturing and sourcing, including shifting towards options such as local production.
• Enhancing supply chain visibility and transparency.
• Evaluating policy and guidance on supply and stockpiling.

Impact key challenges facing the supply chain to enhance resilience, streamline operations, and ensure consistent drug availability.

Significant uncertainty surrounds drug reimbursement in Quebec, as the healthcare system undergoes major reform. This session will provide a high-level overview of the current landscape, including:

• INESSS under pressure: Budget constraints and the challenge of keeping pace with the Canada Drug Agency.
• Limitations of the public drug plan: Inability to cover numerous new treatments for rare diseases, including upcoming cell and gene therapies.
• System reform and Santé Québec: The creation of Santé Québec reshapes operational responsibilities — with major implications for group purchasing, hospital pharmacies, and service delivery.

Explore the key challenges for market access in Quebec and open the floor for your questions.

The federal government has committed $1.5 billion over three years to help provinces and territories cover the costs of high-priced rare disease treatments. Implementing the National Strategy for Drugs for Rare Diseases requires ongoing collaboration, transparency, and adaptability among all stakeholders. Walk away with an action plan on:

• Understanding the challenges still faced by patients across Canada on receiving access to the right treatments.
• Assessing the steps towards collaboration made in 2025 at the provincial, federal, and industry level.
• Exploring how this funding has reduced treatment delays, improved patient outcomes, and fostered a more sustainable rare disease drug ecosystem.

Improve coordination of access to treatments for rare disease patients to ensure timely, equitable access to life-saving therapies and enhance overall patient outcomes.

Private payers play a crucial role in ensuring Canadians have access to innovative treatments. By bridging the gap between public coverage and out-of-pocket expenses, private insurers help patients receive timely and comprehensive healthcare solutions. Master the success factors to:

• Understand how private payers enhance access to treatment for patients.
• Explore how private payers can collaborate with pharmaceutical companies, healthcare providers, and employers to develop sustainable reimbursement models.
• Examine the role of innovative drug coverage programs, value-based agreements, and digital health solutions in improving patient outcomes.

Heighten collaboration between private payers and healthcare stakeholders to optimize patient access and treatment outcomes.

Step into a dynamic conversation where diverse voices from across the market access landscape share their top three “I wish…” statements — honest, bold, and sometimes surprising. Discover where visions align and where tensions spark in the collective pursuit of better market access. Deepen your knowledge on the future of market access by:

• Hearing candid reflections from key stakeholders, including patient groups, payers, HTA agencies, clinicians, and industry leaders.
• Exploring areas of common ground and identifying key divergences, with the aim of improving access pathways.
• Gaining a deeper understanding of what real change could look like, directly from those who are experiencing it firsthand.

Excel in shaping the future of market access by turning bold ideas and shared insights into actionable strategies to create more sustainable pathways for patients to access the treatments they need.

Review the key solutions and takeaways from the conference. Source a summary of action points to implement in your work.